A Boston VC firm is launching a new neuroscience company with a $93M investment that aims to treat disorders including ...

Helmed by Roche alums, Newleos Therapeutics is taking over four drugs dropped from the Swiss pharma’s pipeline in early 2024.

Cybin Inc. (NYSE American:CYBN) (Cboe Canada CA:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing ...

Newleos Therapeutics is making its debut with $93.5 million aimed at developing safer and more effective neuroscience treatments with several clinical programs from Swiss major Roche in hand. | ...

Fresh off a reorganization, Biogen’s research leader Jane Grogan says the biotech has to 'look outside the walls of the ...

Sage Therapeutics Inc. pushed off questions about potential mergers or acquisitions during its first earnings call since ...

Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced the appointment of Nancy S. Lurker to its Board of Directors, ...

The 12-month price targets, analyzed by analysts, offer insights with an average target of $8.86, a high estimate of $14.00, ...

A new study found that older adults with fluctuating cholesterol levels—regardless of how high—could be 60% more likely to ...

Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its ...

Bristol Myers Squibb clocked $10 million in sales for new schizophrenia drug Cobenfy in the fourth quarter of 2024, with the ...

Seaport Therapeutics (“Seaport” or the “Company”), a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced the ...